{"id":19141,"date":"2020-05-05T14:18:05","date_gmt":"2020-05-05T12:18:05","guid":{"rendered":"http:\/\/miunidad.eu\/porib.com\/?p=19141"},"modified":"2022-07-04T14:19:53","modified_gmt":"2022-07-04T12:19:53","slug":"ahorro-de-costes-con-tofacitinib-en-pacientes-con-artritis-reumatoide","status":"publish","type":"post","link":"https:\/\/porib.com\/en\/ahorro-de-costes-con-tofacitinib-en-pacientes-con-artritis-reumatoide\/","title":{"rendered":"Ahorro de costes con tofacitinib en pacientes con artritis reumatoide"},"content":{"rendered":"<p>La inclusi\u00f3n de tofacitinib como terapia inicial en secuencias de tratamiento para la artritis reumatoide de moderada a grave demostr\u00f3 ser una estrategia dominante (m\u00e1s eficacia y menos costes) frente a secuencias con terapias biol\u00f3gicas est\u00e1ndar en pacientes con fracaso o intolerancia a f\u00e1rmacos antirreum\u00e1ticos modificadores de la enfermedad sint\u00e9ticos convencionales* (poblaci\u00f3n csDMARD-IR) y supone ahorro de costes y similar eficacia tras fallo con inhibidores del factor de necrosis tumoral (poblaci\u00f3n TNFi-IR), seg\u00fan se recoge en el an\u00e1lisis coste-efectividad publicado en la revista\u00a0<em>Clinical Rheumatology<\/em>:\u00a0<em>Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain,\u00a0<\/em>de los autores Navarro F, Martinez-Sesmero JM, Balsa A, Peral C, Montoro M, Valderrama M, G\u00f3mez S, de Andr\u00e9s-Nogales F, Casado MA y Oyag\u00fcez I.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La inclusi\u00f3n de tofacitinib como terapia inicial en secuencias de tratamiento para la artritis reumatoide de moderada a grave demostr\u00f3 ser una estrategia dominante (m\u00e1s eficacia y menos costes) frente a secuencias con terapias biol\u00f3gicas est\u00e1ndar en pacientes con fracaso o intolerancia a f\u00e1rmacos antirreum\u00e1ticos modificadores de la enfermedad sint\u00e9ticos convencionales* (poblaci\u00f3n csDMARD-IR) y supone&#8230; <\/p>\n<div class=\"clear\"><\/div>\n<p><a href=\"https:\/\/porib.com\/en\/ahorro-de-costes-con-tofacitinib-en-pacientes-con-artritis-reumatoide\/\" class=\"excerpt-read-more\">Read More<i class=\"fa fa-caret-right icon-caret-right\"><\/i><\/a><\/p>\n","protected":false},"author":4,"featured_media":19142,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[67],"tags":[],"class_list":["post-19141","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ultimas-noticias"],"translation":{"provider":"WPGlobus","version":"2.10.3","language":"en","enabled_languages":["es","en"],"languages":{"es":{"title":true,"content":true,"excerpt":false},"en":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/19141"}],"collection":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/comments?post=19141"}],"version-history":[{"count":1,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/19141\/revisions"}],"predecessor-version":[{"id":19143,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/19141\/revisions\/19143"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media\/19142"}],"wp:attachment":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media?parent=19141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/categories?post=19141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/tags?post=19141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}